2026-07-10 | The Emerging Therapeutic Landscape of Bullous Pemphigoid: A Systematic Registry-Based Analysis of Clinical Trials (2015-2025).
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, with increasing incidence and substantial morbidity in elderly patients. Recent advances in understanding BP pathogenesis have led to the development of targeted therapies. However, the clinical trial landscape remains fragmented, and a comprehensive overview of emerging therapies is lacking. We performed a systematic analysis of interventional clinical trials registered in ClinicalTrials.gov between January 1, 2015, and December 31, 2025. Trials were identified using the condition terms "bullous pemphigoid" or "pemphigoid" and screened manually according to predefined eligibility criteria. Extracted data included trial design, enrollment, interventions, mechanisms of action, and outcome measures. Trials were categorized by therapeutic mechanism, and heterogeneity in endpoint definitions and use of validated instruments was assessed. Fourteen interventional trials evaluating emerging pharmacological therapies were included. Trial activity increased markedly after 2019, with predominance of industry-sponsored studies (64.3%). Investigated mechanisms included FcRn inhibition, complement pathway inhibition, type 2 inflammation targeting, interleukin (IL)-17/IL-23 axis modulation, CCR3 antagonism, and B-cell/immunoglobulin E (IgE)-targeted approaches. Target enrollment ranged from 5 to 200 participants. High rates of trial discontinuation were observed (42.9% terminated or withdrawn), with reported reasons including futility analyses, strategic sponsor decisions, operational challenges, and administrative factors. Substantial heterogeneity in primary endpoints was identified, with only 35.7% of trials explicitly referencing international consensus definitions. Validated instruments such as the Bullous Pemphigoid Disease Area Index (BPDAI) were widely used (85.7%), while quality-of-life measures were less frequently incorporated (35.7%). The BP clinical trial landscape has expanded significantly, reflecting increasing interest in mechanism-targeted therapies. However, heterogeneity in endpoint definitions and incomplete adoption of validated outcome measures remain key barriers to evidence synthesis. Standardization of clinical trial design and endpoints is essential to facilitate comparison across studies and accelerate therapeutic development in BP.
Open article ↗
2026-06-24 | Emerging Paediatric Uses of Dupilumab Beyond Approvals.
Dupilumab is a fully human IgG4 monoclonal antibody that targets the interleukin-4 receptor alpha subunit, thereby inhibiting interleukin-4 and interleukin-13 signalling, two central drivers of type-2 (T2) inflammation. It is currently approved by both the Food and Drug Administration and the European Medicines Agency for multiple indications, including moderate-to-severe atopic dermatitis (from 6 months of age), add-on maintenance therapy for moderate-to-severe asthma with T2 inflammation (≥ 6 years), eosinophilic esophagitis (≥ 1 year and ≥ 15 kg), chronic rhinosinusitis with nasal polyps (≥ 12 years in the United States and ≥ 18 years in Europe), and chronic spontaneous urticaria (≥ 12 years in the United States and ≥ 2 years in Europe) who remains symptomatic despite antihistamine therapy. Additional adult indications include prurigo nodularis, bullous pemphigoid, and chronic obstructive pulmonary disease with an eosinophilic phenotype. Beyond these established indications, increasing evidence suggests a broader therapeutic potential for dupilumab in paediatric diseases characterized by T2 immune dysregulation. This narrative review synthesizes the emerging literature on off-label and investigational paediatric uses of dupilumab, focusing on inflammatory skin diseases, inborn errors of immunity with severe atopic phenotypes, transplant-associated immune dysregulation, selected respiratory conditions and food allergy. Although current evidence largely derives from case reports, small case series, and observational studies, reported outcomes consistently indicate significant improvements in disease severity, and quality of life, with a favourable safety profile. These findings highlight the expanding role of IL-4/IL-13 blockade in paediatrics and underscore the need for prospective studies to better define efficacy, long-term safety, and optimal patient selection in emerging indications.
Open article ↗
2026-06-24 | Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.
Cutaneous adverse drug reactions (cADRs) are unintended and harmful skin responses to medications that impose significant clinical and economic burdens worldwide. The increasing use of novel agents, particularly immune checkpoint inhibitors, has further compounded this challenge. While most cADRs are mild and resolve upon drug discontinuation, approximately 2-6.7% progress to severe, potentially fatal conditions. The most common severe forms include acute generalized exanthematous pustulosis, Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, and drug-associated bullous pemphigoid. Current therapeutic options for refractory cADRs remain limited, primarily relying on systemic corticosteroids, conventional immunosuppressants, and intravenous immunoglobulin. Growing insights into disease pathogenesis and the subsequent repurposing of novel targeted therapies offer promising solutions to the persistent challenges of cADRs. Emerging agents, such as biologics targeting tumor necrosis factor-α, interleukins (IL-4/IL-13, IL-5, IL-6, IL-17, IL-36), immunoglobulin E, and CD20, along with small molecule inhibitors of Janus kinases and phosphodiesterase 4, hold the potential to revolutionize management paradigms, though their long-term efficacy and safety profiles await robust clinical validation.
Open article ↗
